Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
AR-inhibitor Bicalutamide in Treating Patients With TNBC
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 60
- Registration Number
- NCT02353988
Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1
- Registration Number
- NCT02348281
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
- Conditions
- Stage I Prostate CancerStage IIA Prostate CancerProstate AdenocarcinomaStage III Prostate CancerStage IIB Prostate Cancer
- Interventions
- Radiation: Internal Radiation TherapyOther: Laboratory Biomarker AnalysisOther: Quality-of-Life Assessment
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 146
- Registration Number
- NCT02346253
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: AnthracyclinesDrug: TaxanesDrug: DNA intercalators
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
- Conditions
- Detectable Prostate Nodules
- Interventions
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 116
- Registration Number
- NCT02085252
- Locations
- 🇫🇷
Ouzid, Paris La Défense,, Paris, France
🇫🇷Tenon Hospital Paris France, Paris, France
Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
- Conditions
- Adenocarcinoma of the Prostate
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 17
- Registration Number
- NCT02064036
- Locations
- 🇺🇸
UC Davis Sacramento Cancer Center Dept of Radiation Oncology, Sacramento, California, United States
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT02059213
- Locations
- 🇺🇸
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Michigan Hospital, Ann Arbor, Michigan, United States
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
- Conditions
- Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- Procedure: orchiectomyOther: laboratory biomarker analysis
- First Posted Date
- 2014-02-10
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 71
- Registration Number
- NCT02058706
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
- Conditions
- Salivary Gland Cancer
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2024-11-05
- Target Recruit Count
- 149
- Registration Number
- NCT01969578
- Locations
- 🇮🇹
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Azienda Provinciale per i Servizi Sanitari - Ospedale Santa Chiara, Trento, Italy
🇦🇹Medical University Vienna - General Hospital AKH, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.